Table 1.
Baseline characteristics of the patients
| Characteristics | Total (n = 28) |
|---|---|
| Age, years | |
| Mean ± standard deviation | 39.8 ± 12.67 |
| Median (range) | 37 (19–65) |
| Sex, n (%) | |
| Male | 17 (60.7) |
| Female | 11 (39.3) |
| Ethnic group, n (%) | |
| Han | 28 (100.0) |
| Time from first diagnosis, months | |
| Median (Q1–Q3) | 22.0 (10.0–40.2) |
| ECOG PS, n (%) | |
| 0 | 3 (10.7) |
| 1 | 24 (85.7) |
| 2 | 1 (3.6) |
| Previous lines of chemotherapy | |
| Median (Q1–Q3) | 3.0 (2.0–4.5) |
| ≥3, n (%) | 15 (53.6) |
| Previous radiotherapy, n (%) | |
| Yes | 22 (78.6) |
| No | 6 (21.4) |
| Previous autologous stem cell transplantation, n (%) | |
| None | 26 (92.9) |
| Once | 2 (7.1) |
| Asparaginase-based treatment outcome | |
| Refractory | 12 (42.9) |
| Relapsed | 16 (57.1) |
| Bone marrow involvement, n (%) | |
| No | 22 (78.6) |
| Yes | 6 (21.4) |
| B symptoms, n (%) | |
| Presence | 24 (85.7) |
| Absence | 4 (14.3) |
| Lactate dehydrogenase, n (%) | |
| Normal | 10 (35.7) |
| Increased | 18 (64.3) |
| Plasma EBV, n (%) | |
| Positive | 8 (28.6) |
| Negative | 20 (71.4) |
| Ann Arbor stage, n (%) | |
| I | 2 (7.1) |
| II | 7 (25.0) |
| III | 0 |
| IV | 19 (67.9) |
| PINK, n (%) | |
| Low | 9 (32.1) |
| Intermediate | 11 (39.3) |
| High | 8 (28.6) |
| PINK-E, n (%) | |
| Low | 16 (57.1) |
| Intermediate | 9 (32.1) |
| High | 3 (10.7) |
ADA anti-drug antibody, EBV Epstein–Barr virus, ECOG PS Eastern Cooperative Oncology Group performance status, PD progressive disease, PINK Prognostic Index for Natural Killer Lymphoma, risk factors include: age >60 years, stage III or IV, distant lymph node involvement, and non-nasal type disease;22 PINK-E Prognostic Index for Natural Killer Lymphoma with EBV DNA, risk factors include: age >60 years, stage III or IV, distant lymph node involvement, non-nasal type disease, and EBV DNA22